Application of IV 99mTc-tilmanocept for Imaging of Macrophage-specific Inflammation

NCT03523130 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 9

Last updated 2021-02-26

No results posted yet for this study

Summary

The purpose of this study is to evaluate uptake of intravenously administered 99mTc-tilmanocept using single photon emission computed tomography (SPECT/CT) scanning in individuals with HIV and individuals without HIV.

Conditions

Interventions

DIAGNOSTIC_TEST

Imaging

Macrophage-specific inflammation

Sponsors & Collaborators

  • Massachusetts General Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-05-03
Primary Completion
2020-10-30
Completion
2020-10-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03523130 on ClinicalTrials.gov